T-cell receptor Vβ skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: A prospective study by EWOG-MDS

Blood Cancer Journal

Volumn 4, Issue 5, 2014, Pages

  Aalbers, A M ^a,b   Van Den Heuvel Eibrink, M M ^a   Baumann, I ^c   Beverloo, H B ^b   Driessen, G J ^a,b   Dworzak, M ^d   Fischer, A ^e   Gohring G ^f   Hasle, H ^g   Locatelli, F ^h   De Moerloose, B ⁱ   Noellke, P ^e   Schmugge, M ^j   Stary, J ^k   Yoshimi, A ^e   Zecca, M ^l   Zwaan, C M ^a   Van Dongen, J J M ^b   Pieters, R ^a   Niemeyer, C M ^e   Van Der Velden, V H J ^b   Langerak, A W ^b   more..

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Clinical Centre South West   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF FREIBURG   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h UNIVERSITY OF PAVIA   (Italy)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^k UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^l FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; HLA DR15 ANTIGEN; PREDNISOLONE; T LYMPHOCYTE RECEPTOR BETA CHAIN; THYMOCYTE ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; CYTOPENIA; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HEMATOPOIESIS; HETERODUPLEX ANALYSIS; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; REFRACTORY CYTOPENIA OF CHILDHOOD; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE; CASE CONTROL STUDY; CHEMISTRY; CLINICAL TRIAL; IMMUNOLOGY; INFANT; MULTICENTER STUDY; PANCYTOPENIA; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOSUPPRESSION; INFANT; MALE; MYELODYSPLASTIC SYNDROMES; PANCYTOPENIA; PROSPECTIVE STUDIES; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84901999523     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.28     Document Type: Article

References (44)

1. Hasle H, Kerndrup G, Jacobsen BB. Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia 1995; 9: 1569-1572.
2. Hasle H, Wadsworth LD, Massing BG, McBride M, Schultz KR. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol 1999; 106: 1027-1032.
3. Passmore SJ, Chessells JM, Kempski H, Hann IM, Brownbill PA, Stiller CA. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol 2003; 121: 758-767.
4. Niemeyer CM, Baumann I. Classification of childhood aplastic anemia and myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program 2011; 2011: 84-89.
5. Baumann I, Niemeyer CM, Bennett JM, Shannon K. Childhood myelodysplastic syndromes. In: Swerdlow SH, Campo E, Harris NL et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008, pp 104-107.
6. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-2506.
7. Raza A, Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer 2012; 12: 849-859.
8. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithy-mocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99: 699-705.
9. Jonasova A, Neuwirtova R, Cermak J, Vozobulova V, Mocikova K, Siskova M et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 100: 304-309.
10. Asano Y, Maeda M, Uchida N, Yokoyama T, Osaki K, Shimoda K et al. Immuno-suppressive therapy for patients with refractory anemia. Ann Hematol 2001; 80: 634-638.
11. Aivado M, Rong A, Stadler M, Germing U, Giagounidis A, Strupp C et al. Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 2002; 68: 210-216.
12. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137: 156-163.
13. Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 2003; 120: 679-684.
14. Yazji S, Giles FJ, Tsimberidou AM, Estey EH, Kantarjian HM, O'Brien SA et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003; 17: 2101-2106.
15. Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004; 18: 460-465.
16. Broliden PA, Dahl IM, Hast R, Johansson B, Juvonen E, Kjeldsen L et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 2006; 91: 667-670.
17. Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26: 2505-2511.
18. Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/99. J Clin Oncol 2011; 29: 303-309.
19. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithy-mocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998; 102: 1314-1322.
20. Baumann I, Scheid C, Koref MS, Swindell R, Stern P, Testa NG. Autologous lymphocytes inhibit hemopoiesis in long-term culture in patients with myelo-dysplastic syndrome. Exp Hematol 2002; 30: 1405-1411.
21. Chamuleau ME, Westers TM, van Dreunen L, Groenland J, Zevenbergen A, Eeltink CM et al. Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome. Haematologica 2009; 94: 496-506.
22. Zheng Z, Qianqiao Z, Qi H, Feng X, Chunkang C, Xiao L. In vitro deprivation of CD8()CD57()T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome. Exp Hematol 2010; 38: 677-684.
23. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001; 25: 1075-1083.
24. Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002; 100: 3639-3645.
25. Epling-Burnette PK, Painter JS, Rollison DE, Ku E, Vendron D, Widen R et al. Prevalence and clinical association of clonal T-cell expansions in myelodysplastic syndrome. Leukemia 2007; 21: 659-667.
26. Fozza C, Contini S, Galleu A, Simula MP, Virdis P, Bonfigli S et al. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4() subset and oligoclonal in the CD8() subset. Exp Hematol 2009; 37: 947-955.
27. Kook H, Zeng W, Guibin C, Kirby M, Young NS, Maciejewski JP. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 2001; 29: 1270-1277.
28. Meers S, Vandenberghe P, Boogaerts M, Verhoef G, Delforge M. The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: a single centre study of 131 patients. Leuk Res 2008; 32: 1026-1035.
29. Zou JX, Rollison DE, Boulware D, Chen DT, Sloand EM, Pfannes LV et al. Altered naive and memory CD4 T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia 2009; 23: 1288-1296.
30. Yoshimi A, van den Heuvel-Eibrink MM, Baumann I, Schwarz S, Simonitsch-Klupp I, de Paepe P et al. Comparison of horse and rabbit anti-thymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood. Haematologica 2013; 99: 656-663.
31. de Vries AC, Langerak AW, Verhaaf B, Niemeyer CM, Stary J, Schmiegelow K et al. T-cell receptor Vbeta CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC) and severe aplastic anemia. Leukemia 2008; 22: 1170-1174.
32. Langerak AW, van Den Beemd R, Wolvers-Tettero IL, Boor PP, van Lochem EG, Hooijkaas H et al. Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. Blood 2001; 98: 165-173.
33. Comans-Bitter WM, de Groot R, van den Beemd R, Neijens HJ, Hop WC, Groeneveld K et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr 1997; 130: 388-393.
34. Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, Keyvanafar K et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005; 106: 841-851.
35. Sloand EM, Melenhorst JJ, Tucker ZC, Pfannes L, Brenchley JM, Yong A et al. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood 2011; 117: 2691-2699.
36. Dunn DE, Tanawattanacharoen P, Boccuni P, Nagakura S, Green SW, Kirby MR et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999; 131: 401-408.
37. Maciejewski JP, Follmann D, Nakamura R, Saunthararajah Y, Rivera CE, Simonis T et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood 2001; 98: 3513-3519.
38. Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 2002; 100: 3897-3902.
39. Aalbers AM, van der Velden VH, Yoshimi A, Fischer A, Noellke P, Zwaan CM et al. The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS. Leukemia 2013; 28: 189-192.
40. Kook H, Risitano AM, Zeng W, Wlodarski M, Lottemann C, Nakamura R et al. Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens. Blood 2002; 99: 3668-3675.
41. Kotsianidis I, Bouchliou I, Nakou E, Spanoudakis E, Margaritis D, Christophoridou AV et al. Kinetics, function and bone marrow trafficking of CD4CD25 FOXP3 regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 2009; 23: 510-518.
42. Kordasti SY, Afzali B, Lim Z, Ingram W, Hayden J, Barber L et al. IL-17-producing CD4() T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009; 145: 64-72.
43. Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, Afzali B et al. CD4 CD25high Foxp3 regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007; 110: 847-850.
44. Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA et al. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol 2012; 189: 3198-3208.